HC Wainwright Issues Optimistic Estimate for CORT Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Research analysts at HC Wainwright raised their Q1 2025 earnings per share (EPS) estimates for shares of Corcept Therapeutics in a report released on Tuesday, February 11th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings per share of $0.55 for the quarter, up from their prior estimate of $0.36. HC Wainwright currently has a “Buy” rating and a $80.00 target price on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. HC Wainwright also issued estimates for Corcept Therapeutics’ Q2 2025 earnings at $0.60 EPS, Q3 2025 earnings at $0.65 EPS, Q4 2025 earnings at $0.70 EPS, FY2025 earnings at $2.51 EPS, FY2026 earnings at $4.37 EPS, FY2027 earnings at $6.36 EPS and FY2028 earnings at $7.67 EPS.

Several other analysts have also commented on the stock. Sandler O’Neill reissued a “buy” rating on shares of Corcept Therapeutics in a research report on Friday, October 18th. StockNews.com lowered shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 25th. Finally, Canaccord Genuity Group increased their target price on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday, January 30th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $88.25.

Corcept Therapeutics Price Performance

Shares of CORT stock opened at $70.15 on Thursday. The stock’s 50-day moving average is $57.45 and its 200 day moving average is $48.88. Corcept Therapeutics has a 1-year low of $20.84 and a 1-year high of $71.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. The company has a market cap of $7.35 billion, a P/E ratio of 55.68 and a beta of 0.58.

Institutional Investors Weigh In On Corcept Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Capital Performance Advisors LLP purchased a new position in Corcept Therapeutics during the 3rd quarter worth approximately $25,000. Kestra Investment Management LLC purchased a new position in Corcept Therapeutics in the fourth quarter valued at $27,000. National Bank of Canada FI purchased a new position in Corcept Therapeutics in the fourth quarter valued at $42,000. USA Financial Formulas acquired a new position in shares of Corcept Therapeutics in the fourth quarter worth about $54,000. Finally, Newbridge Financial Services Group Inc. purchased a new stake in shares of Corcept Therapeutics during the 4th quarter worth about $58,000. Institutional investors and hedge funds own 93.61% of the company’s stock.

Insider Buying and Selling at Corcept Therapeutics

In other Corcept Therapeutics news, insider Sean Maduck sold 20,000 shares of the firm’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $50.39, for a total value of $1,007,800.00. Following the completion of the transaction, the insider now owns 85,318 shares of the company’s stock, valued at approximately $4,299,174.02. This trade represents a 18.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $68.08, for a total value of $149,776.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 28,011 shares of company stock worth $1,479,608. 20.50% of the stock is owned by insiders.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.